Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Shares Issued (2016 - 2024)

Kiora Pharmaceuticals' Shares Issued history spans 9 years, with the latest figure at $13.3 million for Q4 2024.

  • For Q4 2024, Shares Issued rose 12329.63% year-over-year to $13.3 million; the TTM value through Sep 2025 reached $13.3 million, down 13.61%, while the annual FY2024 figure was $15.0 million, 4784.37% up from the prior year.
  • Shares Issued reached $13.3 million in Q4 2024 per KPRX's latest filing, up from $300000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $17.7 million in Q3 2021 to a low of -$17.7 million in Q4 2021.
  • Average Shares Issued over 4 years is $2.4 million, with a median of $299250.0 recorded in 2023.
  • Peak YoY movement for Shares Issued: crashed 328.44% in 2020, then soared 12329.63% in 2024.
  • A 4-year view of Shares Issued shows it stood at -$4.3 million in 2020, then crashed by 314.29% to -$17.7 million in 2021, then surged by 100.6% to $107079.0 in 2023, then skyrocketed by 12329.63% to $13.3 million in 2024.
  • Per Business Quant, the three most recent readings for KPRX's Shares Issued are $13.3 million (Q4 2024), $300000.0 (Q2 2024), and $15.0 million (Q1 2024).